您好,欢迎来到上海士研管理咨询有限公司
产业峰会 演讲局 专家智库服务 峰会活动服务 整合营销服务
  • 产业峰会:
    以专业团队对产业和市场客观详实地调研为前提,拥有战略性、系统性、全球性的基因,汇集了领导者关注的热点话题与领袖代表,为您提供“一站式”的对话、分享、社交平台!
  • 演讲局:
    致力于为全球企业和机构提供主题演讲家、高管大师班、董事会顾问,每项服务都提供了一种更深入、更具互动性的体验,尤其是针对较小的精选受众和关键个人。我们拥有最具影响力的商业领袖和顶级专家的资源,他们是各自领域的最杰出的代表。我们的团队由经验丰富的演讲和活动经理组成,我们注重建立长期而深入的伙伴关系。
  • 专家智库服务:
    中国领先的行业专家知识信息服务供应商,为需要专业洞见的商业决策者匹配具有一手经验的行业专家,助力他们以更加明确的目标和坚定的信心做出决策。我们有60万余名专家顾问遍布二十多个行业,而且每天还在增加!
  • 峰会活动服务:
    致力于成为全球最专业的产业峰会活动提供商,为企业和机构的产业性峰会活动提供一站式专业服务,包括调研策划、定制邀请、营销推广、运营组织、项目管理、直播与数字化会议等,每项服务都由经验丰富的专业团队匹配长期沉淀的产业资源予以卓越执行,我们注重建立长期而深入的伙伴关系。
  • 整合营销服务:
    致力于成为全球领先的2B营销服务机构,聚焦产业高端活动、内容、渠道的建设与沉淀,为客户提供一站式整合营销解决方案,助力企业线上线下获客与品牌筑造。我们深信专业团队匹配产业资源带来卓越执行,我们注重建立长期而深入的伙伴关系。
嘉宾信息
发布时间: 2023 - 06 - 25
点击次数: 0
所属职位: 副总裁兼首席运营官
所属公司: 贝达药业股份有限公司
个人简介:
香港科技大学高级管理人员工商管理硕士。曾就职于北京同仁医院骨科,在美国百时美施贵宝、法国赛诺菲安万特、美国礼来、英国阿斯利康、美国默沙东等医疗机构和知名药企担任高层管理职务,具有近30年的药物推广渠道建设和药物可及性提升经验,特别是对肿瘤治疗领域的药物在中国市场的应用具有专业影响力。分管公司肿瘤事业部、市场部、商务及市场准入部。
发布时间: 2023 - 06 - 26
点击次数: 0
所属职位: 首席科学家
所属公司: 华润医药
个人简介:
陈波博士是海外高层次人才特聘专家, 目前担任华润医药集团首席科学家, 在生物技术和制药行业拥有超过20年的国际职业生涯,包括在美国NIH,AstraZeneca等顶尖科研机构和制药公司从事基础研究和新药研发团队领导者的工作经历,具有从靶点发现到临床开发和商业运作的整个研发价值链的研发背景。他博士毕业于中国人民解放军空军军医大学,在美国NIH完成博士后,其后还获得美国Hood College工商管理硕士学位。他迄今在著名期刊上发表国际学术论文,专著章节和专利共30余篇,包括发表在Annals of the Rheumatic Diseases, Nature  Communication, Nature Immunology, Nature Medicine, PNAS  等顶尖杂志上的论文。并曾获得了卫生部的科技进步二等奖,AstraZeneca的员工白金奖和银奖,NIH的卓越研究员奖,齐鲁制药集团的卓越领导奖等。Dr. Bo Chen is a specially-appointed expert for overseas high-level talents . He is currently the Chief Scientific Officer at China Resources Pharmaceutical Group Limited.  He has more than 20 years of international career in the biotechnology and pharmaceutical industries, including basic research and innovative drug R&D team leadership in top scientific research institutions and pharmaceutical companies such as the National Institutes of Health, AstraZeneca, etc. He has R&D background in the entire R&D value chain from target discovery to clinical development and commercial operation. He received his PhD. degree from the Air Force Medical University (China), completed the postdoctoral fellowship at the National Institutes of Health in the United States, and later obtained an MBA degree from Hood College (U.S.A). He has published dozens of academic papers, book chapters  and patents in peer-reviewed journals, including papers published in top journals such as Annals of the Rheumatic Diseases, Nature Communication, Nature Immunology, Nature Medicine, PNAS, etc. And has won the second prize of the Ministry of Health's Science and Technology Progress Award, the AstraZeneca Staff Platinum Award and Silver Award, the NIH Outstanding Researcher Award, Qilu Pharmaceutical Group's Outstanding Leadership Award, etc.
发布时间: 2023 - 06 - 25
点击次数: 0
所属职位: 高级副总裁
所属公司: 绿叶制药集团
个人简介:
孙志刚博士现任绿叶制药集团高级副总裁,负责整个集团的国际研发、全球质量、和全球药物警戒等方面的工作。 他也曾在美国担任太阳药业有限公司监管事务副总裁,负责新药和仿制药的上市注册申报及上市后变更管理工作。 加入工业界之前,孙博士曾在美国FDA工作近12年,担任工艺设施办公室(OPF)工艺评审II处代理主任,主要负责新药和仿制药的质量审评和批准前检查(PAI)。他还担任过FDA仿制药办公室(OGD)CMC审评组组长以及FDA驻华办公室(北京)代理药品助理主任。除药物质量审评和GMP现场检查外,孙博士也应邀加入多个FDA技术委员会,参与制定药物审评的内部政策程序及外部企业指南, 并多次获得FDA奖励。目前他应邀担任2020-2025界美国药典委员会委员(USP Expert Committee)和专家组(USP Expert Panel)成员, 以及中国医药创新促进会国际创新药物监管专业委员会委员。Dr. Zhigang Sun is currently Senior Vice President at Luye Pharma Group Ltd.,responsible for international R&D, global quality, and global pharmacovigilance. He previously served as Vice President of Regulatory Affairs at Sun Pharmaceutical Industries, Inc. in the United States, where he was responsible for the marketing registration and post-market change management of new drugs and generic drugs. Prior to joining industry, Dr. Sun worked at U.S. FDA for nearly 12 years, where he served as the acting Branch Chief at Office of Process and Facilities (OPF), and was responsible for  quality review and pre-approval inspection (PAI) of new drugs and generic drugs. He also served as the CMC team Leader at Office of Generic Drugs (OGD), FDA, and the acting Assistant Country Director for Drugs at FDA China Office (Beijing).  In addition to drug review and CGMP inspection, Dr. Sun involved in developing CDER Manual of Policies and Procedures (MaPP) and FDA Guidance for Industry in several FDA technique committees, and has been awarded many times within the FDA owing to his excellent contribution.  He is currently invited to serve as a member of the USP Expert Committee and a member of the USP Expert Panel in 2020-2025, as well as a member of the International Innovative Drug Regulatory Committee of the China Association for the Promotion of Pharmaceutical Innovation.
发布时间: 2023 - 06 - 25
点击次数: 0
所属职位: 研发总经理
所属公司: 济民可信集团上海济煜医药科技有限公司
个人简介:
崔海峰 济民可信集团副总裁,研发中心首席科学家兼总经理。崔海峰毕业于浙江大学高分子化学专业,后参加工作任助理工程师,在浙江省化工研究院从事高分子材料研发工作,期间一成果获国家科学进步二等奖。 1997年进入美国宾西法尼亚大学深造,于2002年获有机化学博士。2002年起加入位于美国费城都会区的英国大型制药公司GSK从事原创新药研发,历任资深科学家,研究员,主任科学家至科学总监,先后领导过十余个新药项目,覆盖靶点发现到临床PoC全流程,目前有四个项目进入临床,其中一个进入临床三期。 主要疾病领域在心血管,传染病,免疫及肿瘤。2019年10月回到中国,加入J&J亚太创新中心任资深总监,负责在亚太地区打造新药研发的生态圈,以及寻求与当地创新公司和科研院所的合作机会,疾病领域包括传染病及疫苗,神经科学,心血管及代谢,和免疫。2021年3月加入济民可信,负责整体的研发工作。Haifeng Cui: Chief Scientific Officer,  Head of R&D, Jemincare Group; SAPA-China Executive CouncilPhD in organic chemistry from University of Pennsylvania. Started his drug discovery career at GSK from 2002 in the USA, worked across several therapeutic areas including cardiovascular, renal disease and infectious disease, over the years led multi-discipline teams delivered several compounds into clinic and follow-up to human PoC. From 2019, he returned to China and jointed J&J, performing search and evaluation for opportunities up to phase 2a to feed into global pipeline, covering infectious disease & vaccine, immunology, neuroscience, cardiovascular & metabolic diseases in the APAC region. Currently he leads the R&D organization of Jemincare Group, advancing an extensive portfolio of innovative medicines into clinical practice.
微信公众号
领导者网络APP
友情链接
Copyright ©2005 - 2017上海士研管理咨询有限公司
犀牛云提供企业云服务